Search results: (10000)
News Adequate Anti-Xa Levels Are More Often Achieved in Trauma Patients When Dosing Enoxaparin Based on Weight
Thromboembolic disease (TED) is a well-known preventable cause of morbidity and mortality in trauma patients. To improve their prognosis, pharmacological thromboprophylaxis, such as with low molecular weight heparins (LMWH), is an essential part of treatment. However, previously published studies have pointed out that standard dosing of LMWH may be associated with insufficient levels of activity measured using the anti-Xa parameter.
News Risk of Developing Inhibitors in People with Milder Forms of Hemophilia
Moderate and mild hemophilia A differ from the severe form not only in clinical course and bleeding risk, but also in the risk of developing neutralizing antibodies (inhibitors).
News How to Secure Diabetics with Atrial Fibrillation During PCI?
Optimal management of patients with atrial fibrillation undergoing percutaneous coronary intervention (PCI) continues to be the subject of studies. A sub-analysis of the RE-DUAL study focused on this issue in a high-risk group of patients with diabetes.
News Physiotherapy as Part of Comprehensive Care for People with Hemophilia – Recommendations vs. Reality
It appears that the physiotherapeutic care provided in reality to people with hemophilia does not align with current recommendations, which see it as an integral part of a multidisciplinary approach. Therefore, in the summer of 2020, an initiative of experts from various countries, including the Czech Republic, was formed to address this issue.
News Undiagnosed Hereditary Angioedema in Pregnancy – Case Study
Delayed diagnosis or misdiagnosis is not uncommon with hereditary angioedema (HAE), especially during pregnancy and the postpartum period. A case study by Canadian authors illustrates that HAE should be considered in the differential diagnosis for any patient with unexplained abdominal pain and recurrent swellings without the presence of urticaria.
News Polatuzumab Vedotin in the Treatment of NHL - News from the 25th EHA Congress
Polatuzumab vedotin (Polivy) is approved in the EU for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), for whom hematopoietic stem cell transplantation (HSCT) is not suitable. We provide an overview of the latest news regarding the role of this modern medicine in the therapy of non-Hodgkin's lymphomas (NHL), presented at the 25th Congress of the European Hematology Association (EHA), held virtually due to the pandemic situation.
News Fixed Combination of Tiotropium/Olodaterol in SMI Inhaler and Its Benefits in COPD Treatment
The TRONARTO study, whose conclusions were published in the International Journal of Chronic Obstructive Pulmonary Disease, addressed the issue of inhalation therapy in patients with chronic obstructive pulmonary disease (COPD). The authors focused on the effect of the combination of tiotropium and olodaterol in an SMI (soft mist inhaler) type inhaler.
News Addition of ixazomib to lenalidomide and dexamethasone in multiple myeloma − Data from real-world Czech practice
A group of Czech and Slovak experts led by Associate Professor Jiří Minařík from the Hemato-Oncology Clinic of the Faculty of Medicine UP and University Hospital Olomouc published the final results of an observational study evaluating the addition of ixazomib to the combination with lenalidomide and dexamethasone in patients with relapsing/refractory multiple myeloma (RRMM). This involves experiences from real clinical practice, with data obtained from the Czech Registry of Monoclonal Gammopathies.
News Good news for sleep in patients with axial spondyloarthritis – ixekizumab effectively reduces night-time back pain
The targeted treatment of axial spondyloarthritis currently relies on the anti-inflammatory effects of tumor necrosis factor (TNF) inhibitors, interleukin IL-17 inhibitors, and Janus kinase (JAK) inhibitors. Besides the objective efficacy of these targeted treatments, it is crucial to describe their influence on subjective symptoms for decision-making in clinical practice. The evaluation of the analgesic effect of ixekizumab (IXE) was provided by the randomized controlled trial COAST-V.
News Prevalence and Clinical Impact of Overweight and Obesity in the Hemophilia Population
Obesity is classified as a lifestyle disease with increasing prevalence and a rising contribution to morbidity and mortality in the general population. The epidemic of overweight and obesity also does not spare individuals with hemophilia. According to epidemiological data, the prevalence of obesity is also increasing in this population, causing a number of complications in many health aspects.
News Third Generation Targeted Therapy for ROS1-Positive NSCLC
The potent third-generation tyrosine kinase inhibitor, lorlatinib, has shown activity in preclinical studies against nearly all known mutations in the ALK and ROS1 genes that lead to resistance to crizotinib treatment. Moreover, lorlatinib crosses the blood-brain barrier, offering hope for patients with CNS metastases. The results of a clinical evaluation of the efficacy and safety of lorlatinib in patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) were published in The Lancet Oncology.
News Is it safe to start dabigatran in the first days after ischemic stroke?
For patients after cardioembolic ischemic stroke (iCMP), starting anticoagulant therapy is crucial, but it is not strictly defined how many days after iCMP it is ideal to begin. The article provides a summary of a recent observational study that investigated the appropriate timing of starting dabigatran in patients with non-valvular atrial fibrillation (NVAF) after their first iCMP who were treated with intravenous thrombolysis or endovascular thrombectomy.
News Alemtuzumab – Does Age Matter? Or Not?
The authors of a study published this year focused on the safety and efficacy of alemtuzumab in patients with relapsing-remitting multiple sclerosis (RRMS). How did it perform over the observed period in patients of different age categories?
News Subcutaneous pdC1-INH in Patients with Hereditary Angioedema in Real-World Practice
Italian authors published a series of cases of patients with hereditary angioedema caused by C1 inhibitor deficiency (C1-INH-HAE) with long-term prophylaxis using human plasma-derived C1 inhibitor concentrate (pdC1-INH) in subcutaneous form. They supplement the results of the placebo-controlled COMPACT study, in which s.c. pdC1-INH reduced the frequency of attacks, with insights from real-world practice in 5 patients treated at the angioedema therapy center in Milan, Italy.
News Interactive Case Study: AATD – Alpha-1-Antitrypsin Deficiency
We present a case study of a man who was 41 years old at the time of his first contact with a pulmonary doctor. He came with symptoms of allergic seasonal rhinoconjunctivitis, proven sensitivity to spring trees, grasses, and dust mites, otherwise healthy, a parrot breeder. He is a former smoker with a smoking history of 20 pack-years. He was examined for exertional dyspnea, cough, recurrent respiratory infections, and wheezing. Try to follow the further diagnostic procedure and considerations with us, where you can choose between different options. At the same time, you will verify whether you proceeded correctly, along with the justification for the step taken.
News Positive Effect of Diosmin on Venous Disease in Terms of Factors Responsible for Angiogenesis
A study published last year monitored the impact of diosmin on laboratory and clinical parameters related to the pathophysiology of chronic venous disease in patients.
News Brentuximab Vedotin and Relapsing/Refractory NHL with High Expression of CD30
A recently published study by authors from South Korea focused on examining the efficacy of brentuximab vedotin in patients with non-Hodgkin lymphomas (NHL) that highly express CD30 (i.e., > 30% CD30-positive tumor cells based on immunohistochemistry), where the disease had relapsed or was refractory to previous treatments.
News Management of Musculoskeletal Issues in Hemophiliacs at a Glance
Musculoskeletal issues are among the most common complications of hemophilia. Prevention and early treatment are crucial, and this message is also addressed to specialists by the World Federation of Hemophilia (WFH) guidelines from 2020.
News Bite-Sized Pieces from EHA 2021: Two New Findings on T-Cell Lymphoma
Can a molecule that is crucial for the sensitivity of adult T-cell lymphoma or leukemia (ATLL) to NK cell cytotoxicity be identified? And what conclusions were drawn from the testing of an antibody specific for TRBC1 in the investigation of T-lymphoproliferative disorders? These topics were also covered at the EHA 2021 congress, in the electronic poster presentation section.
News Clinical Characteristics of Trauma Patients Requiring Dosing Adjustments of Enoxaparin in TEN Prevention
Injuries and trauma surgical procedures represent a significant risk factor for the development of thromboembolic disease (TEN). Routine thromboprophylaxis is thus recommended for trauma patients, often in the form of low molecular weight heparins (LMWH), including enoxaparin. A recently published study evaluated factors associated with the need for higher dosing of enoxaparin to achieve effective prophylactic levels.
News Is It Better to Switch or Cycle in the Treatment of Rheumatoid Arthritis?
The ideal strategy for treating rheumatoid arthritis is still the subject of research. We therefore present the results of a recent study comparing the impact of various therapeutic options when biological treatment is ineffective.
News EAHAD 2024: Fresh results of paradigm5 and 6 studies confirm safety and efficacy of N9-GP
Nonacog beta pegol (N9-GP) is a recombinant factor IX with an extended half-life. Its properties allow for the maintenance of a satisfactorily high level of FIX with intravenous application once a week. At the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), held in early February 2024 in Frankfurt, new findings on this treatment were presented during a satellite symposium by Novo Nordisk.
News Dabigatran Etexilate in the Treatment of Acute Thromboembolic Disease in Children
Until now, standard anticoagulants such as low-molecular-weight heparin or unfractionated heparin and others have been used in pediatric patients for the treatment of thromboembolism. The study presented below aimed to determine whether dabigatran could be the drug of the future in the treatment of pediatric patients with thromboembolism.